A detailed history of R Squared LTD transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, R Squared LTD holds 880 shares of PYXS stock, worth $1,372. This represents 0.0% of its overall portfolio holdings.

Number of Shares
880
Holding current value
$1,372
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$1.54 - $4.77 $1,355 - $4,197
880 New
880 $1.37 Million

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $54.8M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track R Squared LTD Portfolio

Follow R Squared LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of R Squared LTD, based on Form 13F filings with the SEC.

News

Stay updated on R Squared LTD with notifications on news.